Sanofi-Aventis Canada

What Sanofi-Aventis Canada does

Sanofi Canada is the Canadian subsidiary of Sanofi S.A., a France-based multinational pharmaceutical company, and operates as Canada's largest biopharma manufacturer and the only company investing, innovating, and operating across the full life sciences value chain domestically. Headquartered at the Toronto Campus in North York (1755 Steeles Ave W), the largest biotech site in Canada, the company employs 2,000+ people focused on delivering first- and best-in-class medicines and vaccines. The Canadian entity has over 100 years of operating history, with roots dating back to 1917 when the Toronto Campus was originally called 'Laboratory.'

Sanofi's Canadian business is built around an integrated portfolio of prescription products and medical devices, vaccines and immunoprophylaxis products, and patient support programs. Key products include Rezurock (belumosudil tablets) for chronic graft-versus-host disease in patients aged 12+ after failure of at least two prior systemic therapies, and Fluzone High-Dose, an influenza vaccine demonstrating superior protection in adults aged 65+ per the FLUNITY-HD study. The company protects over 7 million Canadians annually against infectious diseases and exports vaccines to over 60 countries. Underlying capabilities include world-leading R&D and biomanufacturing facilities in Toronto, plus a dedicated AI Centre of Excellence at 240 Richmond St W that develops data and AI products to accelerate research and development.

The business model is sales-led and enterprise-focused, monetizing through one-time prescription product sales and vaccine hardware sales distributed via provincial public reimbursement programs, direct healthcare provider channels (hospitals, clinics, pharmacies), and international export partnerships. Customers span government health systems (e.g., Government of Quebec for Rezurock reimbursement), healthcare providers, and end patients reached through public health and vaccination programs. Pricing is managed through public reimbursement negotiations, government health technology assessments (e.g., Canada Drug Agency, INESSS), and standard pharmaceutical pricing models rather than disclosed consumer-facing pricing.

Name

Sanofi-Aventis Canada

Legal name

Sanofi Canada

Website

https://sanofi.ca

Company type

Public

Founded year

1917

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Sanofi Canada is the Canadian subsidiary of Sanofi S.A. and the country's largest biopharma manufacturer, employing 2,000+ people across R&D, biomanufacturing, and an AI Centre of Excellence in Toronto to develop, produce, and distribute prescription medicines, vaccines, and patient support programs domestically and to 60+ countries.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Vaccine Cold Chain, Storage & Distribution (HLAIAEAK), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Prescription pharmaceuticals
• Vaccine manufacturing
• Biopharmaceutical research
• Life sciences products
• Immunology treatments

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Products: Revenue generated from prescription medicines and vaccines sold to healthcare providers, hospitals, and government health programs through public reimbursement and private sales
2. Vaccines: Vaccine products protecting against infectious diseases, distributed domestically to Canadians and exported internationally to over 60 countries

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Sanofi Canada is Canada's largest biopharma manufacturer and the only company investing, innovating, and operating across the full life sciences value chain. It researches, develops, manufactures, and distributes prescription medicines (e.g., Rezurock for chronic graft-versus-host disease) and vaccines (e.g., Fluzone High-Dose for adults 65+), supported by patient support programs. Operations are anchored at the Toronto Campus (R&D and biomanufacturing) and an AI Centre of Excellence in Toronto.

Product overview

Sanofi Canada operates as Canada's largest biopharma manufacturer and the only company investing, innovating and operating across the full life sciences value chain. The company's portfolio consists of prescription products and medical devices (including Rezurock® for chronic GVHD), vaccines and immunoprophylaxis products (including Fluzone High-Dose influenza vaccine), and patient support programs. The company maintains world-leading R&D and biomanufacturing facilities in Toronto, along with an AI Centre of Excellence focused on developing data and AI products to accelerate research and development.

Differentiator

Problem solved

Functional benefit

Products and services

• Rezurock (belumosudil tablets) Prescription medicine (belumosudil tablets) for treating adults and children aged 12 and older with chronic graft-versus-host disease after failure of at least two prior systemic therapies. Sold to hospitals, clinics, and pharmacies; reimbursed via provincial drug plans.
• Fluzone High-Dose Influenza Vaccine

Quantifiable outcome

• Significant reduction in hospitalizations among adults 65+ against laboratory-confirmed influenza, pneumonia, cardio-respiratory hospitalizations, and all-cause hospitalizations compared to standard-dose vaccines

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature1 record

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• AbbVie Canada: AbbVie Canada is a major specialty biologic and immunology pharmaceutical manufacturer in Canada, directly competing with Sanofi in immunology indications (e.g., chronic GVHD overlap with Humira/Skyrizi franchises) for Canadian reimbursement and prescriber share.
• AstraZeneca Canada: AstraZeneca Canada markets a comparable portfolio of prescription pharmaceuticals and biologics in Canada, including respiratory and oncology products that overlap with Sanofi's therapeutic areas, and competes directly for reimbursement and physician adoption.
• Eli Lilly Canada: Eli Lilly Canada is the Canadian subsidiary of Eli Lilly, a major pharmaceutical manufacturer with comparable biologics, vaccines (e.g., COVID), and chronic-disease franchises that compete directly in Canadian reimbursement and prescriber markets.
• Pfizer Canada: Pfizer Canada is the Canadian subsidiary of Pfizer Inc., a global pharmaceutical manufacturer with comparable prescription medicines, vaccines (including mRNA COVID vaccines), and biomanufacturing operations. Both compete for the same Canadian healthcare providers, public reimbursement listings, and vaccine market share.
• GSK Canada: GSK Canada is a major vaccines and specialty pharmaceuticals competitor with overlapping influenza and adult vaccine portfolios. Both companies compete directly in Canadian public health immunization programs and respiratory vaccine categories.
• Novartis Pharmaceuticals Canada: Novartis Pharmaceuticals Canada operates a comparable prescription pharmaceutical business in Canada, including biologics, specialty medicines, and clinical research. It competes for the same healthcare-provider prescribing and provincial reimbursement listings.
• Merck Canada (MSD): Merck Canada, the Canadian arm of MSD, operates a comparable pharmaceutical business spanning vaccines (e.g., Gardasil), biologics, and specialty prescription medicines, and directly competes for Canadian reimbursement listings and healthcare-provider share-of-voice.
• Roche Canada: Roche Canada is the Canadian subsidiary of Roche, a global pharmaceutical and diagnostics company. It competes in specialty biologics and personalized therapeutics, sharing the same Canadian reimbursement and prescriber channels as Sanofi.
• Johnson & Johnson Innovative Medicine Canada: J&J Innovative Medicine Canada is the Canadian pharmaceutical arm of Johnson & Johnson, with comparable biologic and specialty pharmaceutical offerings across immunology and oncology that compete with Sanofi in Canadian reimbursement listings.
• Bristol-Myers Squibb Canada: BMS Canada operates a comparable specialty pharmaceutical business in oncology, immunology, and cardiovascular therapy. It directly competes with Sanofi for the same healthcare provider, hospital, and public reimbursement channels in Canada.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/sanoficanada

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanofi-Aventis Canada